Table 2.
Univariate and multivariate Cox progression analysis of baseline variables for renal progression in primary PMNs.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| HR: 95% CI | p Value | HR: 95% CI | p Value | |
| Male (%) | 1.18 (0.73–1.92) | 0.49 | ||
| Age (y) | 1.06 (1.04–1.08) | <0.01 | 1.06 (1.03–1.08) | <0.01 |
| Microscopic Hematuria (%) | 0.79 (0.49–1.25) | 0.31 | ||
| Urine protein (g/24 h) | 1.02 (0.96–1.09) | 0.48 | ||
| Albumin (g/L) | 0.97 (0.94–1.01) | 0.11 | ||
| eGFR-EPI (mL/min × 1.73 m2) | 0.98 (0.97–0.99) | <0.01 | 1.004 (0.99–1.02) | 0.50 |
| Uric acid (umol/L) | 1.001 (0.999–1.004) | 0.32 | ||
| Hypertension (%) | 1.75 (1.10–2.80) | 0.02 | 0.92 (0.55–1.57) | 0.77 |
| Diabetes Mellitus (%) | 2.89 (1.71–4.90) | <0.01 | 2.35 (1.35–4.09) | <0.01 |
| Immunosuppressive therapy (%) | 2.73 (1.36–5.48) | 0.01 | ||
| Pathology stage (%) | ||||
| I | reference | |||
| II | 1.32 (0.72–2.40) | 0.37 | ||
| III + IV | 1.37 (0.62–3.03) | 0.44 | ||
| Tubulo-interstitial lesions ≥ 25 (%) | 2.98 (1.08–8.18) | 0.03 | 2.34 (0.76–7.19) | 0.14 |
| Serum PLA2R ab and glomerular PLA2R staining | ||||
| SAb−/GAg− | reference | reference | ||
| SAb+/GAg− | 9.13 (2.28–36.62) | <0.01 | 9.17 (2.26–37.16) | <0.01 |
| SAb+/GAg+ | 3.26 (1.17–9.07) | 0.02 | 2.32 (0.83–6.53) | 0.11 |
| SAb−/GAg+ | 1.92 (0.65–5.67) | 0.24 | 1.53 (0.51–4.60) | 0.45 |